Clinical Efficacy of Sodium Deoxyribonucleate in the Treatment of Acute Respiratory Infections

Anna A. Zuikova, Olga N. Krasnorutskaya, Julia A. Kotova, Daniel Yu. Bugrimov, Olga V. Kashaeva, Natalia M. Sizova

International Journal of Biomedicine. 2019;9(1):52-56.
DOI: 10.21103/Article9(1)_OA10
Originally published March 15, 2019


The aim of the study was to evaluate the effectiveness of sodium deoxyribonucleate (spray) in the treatment of patients with acute respiratory infections (ARI) in the outpatient setting.
Materials and Methods: We conducted a randomized controlled clinical trial. The study included 112 patients aged from 18 to 73 years with an established diagnosis of ARI and a duration of symptoms of the disease no more than 48 hours. The investigational drug – a 0.25% solution of sodium deoxyribonucleate (SD) for external and topical use (spray bottle, 10 ml). Group 1 included 54 patients who received SD: 2 intranasal doses into each nostril every 1-1.5 hours during the first days of the onset of the ARI symptoms; then - 2 doses into each nostril 3 times per day against the background of symptomatic therapy for 5 days. Symptomatic therapy included decongestants, antipyretics, mucolytics and antitussives (if necessary). Group 2 included 58 patients who received only symptomatic therapy. Medical examination was performed daily for 5 days.
Results: Including a 0.25% SD spray solution in the ARI treatment regimen effectively affects the dynamics of the ARI symptoms. SD in the treatment scheme from the first day allows eliminating the main ARI symptoms much faster and more efficiently than the standard treatment regimen; in particular, recovery is accelerated by 2-3 days. Complex therapy including SD causes a 3-fold increase in the level of sIgA in the nasal mucosa of patients on the fifth day of treatment, which indicates a pronounced immunomodulating effect of this intervention, a potential reduction in the risk of complications and recurrence of viral diseases.

acute respiratory infections • secretory immunoglobulin A • squamous epithelium • symptomatic therapy.
  1. Andreeva IV, Stetsyuk OU. [Respiratory tract infections: a new look at old problems]. Klinicheskaja mikrobiologija i antimikrobnaja himioterapijaerapy. 2009;11(2):143–51.[Article in Russian].
  2. Lipatov MK. [The social significance of ARVI and the relevance of symptomatic treatment]. Russkii meditsinskii zhurnal. 2006;14(24):1569-74. [Article in Russian].
  3. Zharkova NE. [Symptomatic treatment of ARVI: the future for combined drugs]. Russkii meditsinskii zhurnal. 2006;15(22):1636-9. [Article in Russian].
  4. Morozova SV. [Treatment of acute upper respiratory tract infections]. Russkii meditsinskii zhurnal. 2005;13(26):1748-51. [Article in Russian].
  5. Sinopalnikov AI, Belotserkovskaya YuG. [Influenza]. Lechachshii vrach.2007;(8):16-21. [Article in Russian].
  6. Fernandes-Matano L, Monroy-Muñoz IE, Angeles-Martínez J, Sarquiz-Martinez B, Palomec-Nava ID, Pardavé-Alejandre HD, et al. Prevalence of non-influenza respiratory viruses in acute respiratory infection cases in Mexico. PLoS One. 2017 May 3;12(5):e0176298. doi: 10.1371/journal.pone.0176298.
  7. Gurov A.V. [Swelling of the mucous membrane of the upper respiratory tract. How to deal with it?].  Russkii meditsinskii zhurnal. 2009;17(18):1–4. [Article in Russian].
  8. Pchelintsev MV. [New clinical and pharmacological aspects of symptomatic treatment of ARVI and influenza]. Russkii meditsinskii zhurnal. 2009;17(14):924–8. [Article in Russian].
  9. Bloom B, Cohen RA, Freeman G. Summary health statistics for U.S. children: National Health Interview Survey, 2008. Vital Health Stat 10. 2009;(244):1-81.
  10. Mäkelä MJ, Puhakka T, Ruuskanen O, Leinonen M, Saikku P, Kimpimäki M, Blomqvist S, Hyypiä T, Arstila P. Viruses and bacteria in the etiology of the common cold. J Clin Microbiol. 1998;36(2):539-42.
  11. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA. 1999 Oct 20;282(15):1440-6.
  12. Kryukov AI. [Symptomatic therapy in acute respiratory diseases]. Spravochnik poliklinicheskogo vracha. 2005;4(4):123-6. [Article in Russian].
  13. Filatov OYu, Kashaeva OV, Bugrimov DJu, Klimovich AA. [Morphophysiological principles of immunological effect of eukaryotic DNA]. Rossiiskii immunologicheskii zhurnal. 2013;7(4):385-90. [Article in Russian].
  14. Gonzales Р, Bartlett JG, Besser RE, Cooper RJ, Hickner JM, Hoffman JR, Sande MA. Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods. Ann Intern Med. 2001 Mar 20;134(6):479-86.
  15. Gwaltney JM Jr, Druce HM.  Efficacy of brompheniramine maleate for the treatment of rhinovirus colds. Clin Infect Dis. 1997 Nov;25(5):1188-94.
  16. Prymula Р, Siegrist CA, Chlibek R, Zemlickova H, Vackova M, Smetana J, et al. Effect of prophylactic paracetamol administration at time of vaccination on febrile reactions and antibody responses in children: two open-label, randomised controlled trials. Lancet. 2009;374(9698):1339-50. doi: 10.1016/S0140-6736(09)61208-3.
  17. Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, et al. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology. 2004 Oct;113(2):212-23.
  18. Pikuza OI, Fayzullina RA, Suleymanova ZY, Zakirova AM, Serdinskaya IN. [Efficacy of Sodium deoxyribonucleate in community-acquired pneumonia in children of school age]. Kazan Medical Journal. 2017;98(5):736-742. [Article in Russian].

Download Article
Received February 5, 2019.
Accepted March 5, 2019.
©2019 International Medical Research and Development Corporation.